KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Total Debt (2016 - 2025)

Biogen has reported Total Debt over the past 16 years, most recently at $6.3 billion for Q4 2025.

  • Quarterly results put Total Debt at $6.3 billion for Q4 2025, changed 0.14% from a year ago — trailing twelve months through Dec 2025 was $6.3 billion (changed 0.14% YoY), and the annual figure for FY2025 was $6.3 billion, changed 0.14%.
  • Total Debt for Q4 2025 was $6.3 billion at Biogen, up from $150.0 million in the prior quarter.
  • Over the last five years, Total Debt for BIIB hit a ceiling of $6.9 billion in Q4 2023 and a floor of $150.0 million in Q2 2025.
  • Median Total Debt over the past 5 years was $6.3 billion (2022), compared with a mean of $4.5 billion.
  • Biggest five-year swings in Total Debt: soared 528.67% in 2022 and later dropped 9.26% in 2024.
  • Biogen's Total Debt stood at $999.1 million in 2021, then soared by 528.67% to $6.3 billion in 2022, then grew by 10.46% to $6.9 billion in 2023, then dropped by 9.26% to $6.3 billion in 2024, then dropped by 0.14% to $6.3 billion in 2025.
  • The last three reported values for Total Debt were $6.3 billion (Q4 2025), $150.0 million (Q2 2025), and $6.3 billion (Q4 2024) per Business Quant data.